The Medicines Co. (MDCO)

The Medicines Company's (MDCO - Analyst Report) third-quarter loss per share of 6 cents missed the Zacks Consensus Estimate of a loss of 5 cents. Although Angiomax continues to contribute significantly to revenues, we are concerned about the product losing exclusivity in the U.S. in September 2010.

The entry of generics would be devastating for the company. Therefore, the onus is on management to acquire and develop the next generation of products to drive the top-line. One of those products was expected to be Cangrelor. However, the failure of the phase III CHAMPION program was a significant setback.

Meanwhile, the Cleviprex sales ramp has also been slow. We recommend avoiding the name until we gain more visibility on the Angiomax patent situation, the Cleviprex ramp and the future of Cangrelor and Oritavancin.

The Medicines Co. (MDCO) : FULL ANALYST REPORT

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES BEAR OF THE DAY ARCHIVE

Zacks Blog: Zacks Industry Outlook Highlights: GlaxoSmithKline, Eli Lilly & Co., The Medicines Company and Genzyme Corporation
(GSK, LLY, MDCO, GENZ)	01/29/10
Zacks Blog: Medicines Co. Upgraded to Neutral
(MDCO)	01/04/10
Zacks Equity Research: Report For MDC3
N/A	12/30/09
Zacks Blog: MDCO Recalls Cleviprex Lots
(MDCO, TEVA)	12/18/09
Zacks Blog: Angiox Label Expanded
(MDCO)	12/03/09

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!